Atherosclerosis and Hyperlipidemia

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
ESC 23: LIBerate-HeFH Study

Frederick Raal,

Watch time: 4m 16s
ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue,

Watch time: 3m 22s

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)
ACC 23: Lipid Management & the CLEAR Trial with Dr Michos

Erin D Michos,

Watch time: 5m 34s
View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 36s
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients

Christie Ballantyne,

Watch time: 3m 44s
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s

Heather Currie , Christine Williams ,

Read time: 10m

Edward T Carreras , Donna M Polk ,

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Sergio Fazio ,

Marc Sirol ,

Donald E Cutlip ,

Watch time: 1h 7m 2s (4 videos)

Marc P Allard-Ratick , Pratik Sandesara , Arshed A Quyyumi , et al

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)

Jiaqian Xu , Michael D Shapiro ,

Kilmer S McCully ,

Media

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Watch time: 1h 7m 2s (4 videos)
ACC 2022 Late-breaker Discussion: The SuperWIN Trial

Dylan L Steen, Harriette Van Spall,

Watch time: 16m 57s

Media

ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue,

Watch time: 3m 22s
ESC 23: LIBerate-HeFH Study

Frederick Raal,

Watch time: 4m 16s

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s

Watch time: 1h 7m 2s (4 videos)
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
Randomized Placebo-Controlled Trial Of Anacetrapib interview with Christopher P. Cannon

Christopher P Cannon,

Watch time: 5m 49s
AHA 2019: Updates from the EVAPORATE Study

Matthew J Budoff,

Watch time: 3m 25s
AHA 2020: Evinacumab safety and efficacy in HoFH

Watch time: 7m 44s
AHA 2020: The STRENGTH Trial

Watch time: 9m 40s

Articles

Current Evidence and Future Directions of PCSK9 Inhibition

Jiaqian Xu

,

Michael D Shapiro

,

Published:

16 February 2021

Citation:

US Cardiology Review 2021;15:e01.

DOI:

https://doi.org/10.15420/usc.2020.17
  • Views: Views 3300
  • Downloads: Downloads 155

HDL Cholesterol and Adverse Outcomes

Marc P Allard-Ratick

,

Pratik Sandesara

,

Arshed A Quyyumi

,

Laurence S Sperling

,

Published:

12 March 2019

Citation:

US Cardiology Review 2019;13(1):49–53

DOI:

https://doi.org/10.15420/usc.2019.3.2
  • Views: Views 3386
  • Downloads: Downloads 33
  • Citations: 5

Novel Treatments for Cardiovascular Disease

Leo Buckley

,

Ahmed Aldemerdash

,

Citation:

US Cardiology Review 2017;11(2):98–104.

DOI:

https://doi.org/10.15420/usc.2017:20:2
  • Views: Views 1984
  • Downloads: Downloads 8

Dyslipidemia: Current Therapies and Guidelines for Treatment

Edward T Carreras

,

Donna M Polk

,

Citation:

US Cardiology Review 2017;11(1):10–5

DOI:

https://doi.org/10.15420/usc.2016:9:2
  • Views: Views 29096
  • Downloads: Downloads 30
  • Citations: 3